Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

SHSE:603707 Stock Report

Market Cap: CN¥21.8b

Nanjing King-Friend Biochemical PharmaceuticalLtd Future Growth

Future criteria checks 5/6

Nanjing King-Friend Biochemical PharmaceuticalLtd is forecast to grow earnings and revenue by 70.5% and 25.5% per annum respectively. EPS is expected to grow by 72.7% per annum. Return on equity is forecast to be 17.3% in 3 years.

Key information

70.5%

Earnings growth rate

72.7%

EPS growth rate

Pharmaceuticals earnings growth18.8%
Revenue growth rate25.5%
Future return on equity17.3%
Analyst coverage

Good

Last updated18 Nov 2024

Recent future growth updates

Recent updates

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.'s (SHSE:603707) Popularity With Investors Is Under Threat From Overpricing

Nov 27
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.'s (SHSE:603707) Popularity With Investors Is Under Threat From Overpricing

Would Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Be Better Off With Less Debt?

Sep 30
Would Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Be Better Off With Less Debt?

Investors Still Waiting For A Pull Back In Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707)

Aug 26
Investors Still Waiting For A Pull Back In Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707)

Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Is Making Moderate Use Of Debt

Jun 26
Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Is Making Moderate Use Of Debt

Getting In Cheap On Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707) Might Be Difficult

May 26
Getting In Cheap On Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE:603707) Might Be Difficult

Earnings and Revenue Growth Forecasts

SHSE:603707 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20266,8621,611N/A9296
12/31/20255,6361,216N/A5907
12/31/20244,303863N/A2186
9/30/20243,877-4238531,503N/A
6/30/20243,770-4099911,595N/A
3/31/20243,628-3451,2691,698N/A
12/31/20233,931-1891,2001,619N/A
9/30/20234,0041,0238291,135N/A
6/30/20234,0411,101437727N/A
3/31/20233,8441,093142466N/A
12/31/20223,7131,091125595N/A
9/30/20223,7581,1224941,069N/A
6/30/20223,9111,1184621,035N/A
3/31/20223,9801,116376929N/A
12/31/20213,6871,059243684N/A
9/30/20213,5371,038-163242N/A
6/30/20213,270953-478-99N/A
3/31/20213,064875-820-469N/A
12/31/20202,915806-860-566N/A
9/30/20202,800770-869-761N/A
6/30/20202,689724-916-816N/A
3/31/20202,594660-850-744N/A
12/31/20192,470605-957-841N/A
9/30/20192,224539-711-553N/A
6/30/20192,027487-400-285N/A
3/31/20191,875452-279-184N/A
12/31/20181,700425-2062N/A
9/30/20181,633425-171-85N/A
6/30/20181,479418N/A-31N/A
3/31/20181,325380N/A-142N/A
12/31/20171,113314N/A-235N/A
9/30/2017915276N/A-268N/A
6/30/2017758193N/A-390N/A
3/31/2017668284N/AN/AN/A
12/31/2016582257N/A-287N/A
12/31/201546988N/A137N/A
12/31/201441650N/A179N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 603707 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.8%).

Earnings vs Market: 603707 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 603707 is expected to become profitable in the next 3 years.

Revenue vs Market: 603707's revenue (25.5% per year) is forecast to grow faster than the CN market (13.7% per year).

High Growth Revenue: 603707's revenue (25.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 603707's Return on Equity is forecast to be low in 3 years time (17.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 10:02
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Yong Jian LiChina Merchants Securities Co. Ltd.
Shitong HanCitic Securities Co., Ltd.